Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 17Carcinoma, Hepatocellular 5Neoplasms 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Liver Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uveal Melanoma 2Stomach Neoplasms 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasm Metastasis 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Basal Cell 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Skin Neoplasms 1

Interventions

pembrolizumab 26Cisplatin 24Carboplatin 19Magnetic Resonance Spectroscopy 16Paclitaxel 15Specimen Handling 14Pemetrexed 12durvalumab 9Radiotherapy, Intensity-Modulated 8Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Nivolumab 7Radiation 6Docetaxel 6Cetuximab 6Biopsy 6osimertinib 5cemiplimab 5Taxes 5Radiotherapy 5Ipilimumab 5Cyclophosphamide 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5poly ICLC 4cabozantinib 4atezolizumab 4Oxaliplatin 4Gemcitabine 4Fluorouracil 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × relatlimab × 1 year × Clear all
NCT05347212 2026-04-15

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡